Quick revision ↓ Medical Dictionary
Deep Learning — Module 16
Connect symptoms and examination findings to a differential, targeted investigations, initial priorities and reassessment.
Describing the skin
Record lesion type, distribution, color, scale, surface, timing, itch or pain and mucosal or systemic involvement. A macule is flat, a papule is raised and solid, and a vesicle contains fluid; description should precede a diagnostic label. Examine relevant nails, hair and other sites with consent. Skin appearance varies across skin tones, so warmth, tenderness, swelling and patient-reported change can be important alongside visible redness.
Common inflammatory patterns
Eczema often involves itchy inflamed skin and barrier dysfunction, while psoriasis commonly produces well-demarcated plaques with scale and may involve nails or joints. Distribution and history guide diagnosis, with infection or contact exposure among alternatives. Management includes trigger and skin-care assessment and appropriate topical or systemic treatment. Potency, body site, duration and follow-up matter for topical steroids; do not assume one preparation suits every rash.
Infection and infestation
Cellulitis is a clinical diagnosis involving skin and soft-tissue infection, but mimics such as venous inflammation or dermatitis occur. Rapid progression, severe pain, systemic toxicity or tissue changes raise concern for deeper infection and urgent assessment. Fungal disease and scabies need suitable recognition and treatment, including contact or environmental measures where appropriate. Repeated steroid use can modify infection appearance and delay correct diagnosis.
Allergy and anaphylaxis
Urticaria produces transient wheals, while angioedema affects deeper tissues. Anaphylaxis is a severe systemic reaction with airway, breathing or circulation problems and may occur without prominent skin findings. Stop the suspected exposure where possible, summon urgent help and follow the emergency pathway, including intramuscular adrenaline when indicated by trained care. Antihistamines do not replace treatment of life-threatening airway or circulatory compromise.
Severe reactions and skin cancer
A new medicine followed by painful widespread rash, mucosal lesions, blistering, fever or organ dysfunction requires urgent assessment for a severe cutaneous adverse reaction. Document the exposure timeline and seek specialist advice. A changing, bleeding or otherwise suspicious skin lesion needs appropriate evaluation; visual heuristics support but do not replace diagnosis. Safety-net persistent lesions and avoid reassuring solely because a lesion is painless or small.
High-Yield Revision
- Describe morphology and distribution before naming a rash.
- Anaphylaxis can occur without obvious skin signs.
- Painful rash with mucosal involvement can be an emergency.
Common Exam & Concept Pitfalls
- Do not use antihistamines as the sole treatment for anaphylactic shock.
- Do not apply the same topical steroid to every rash and site.
Sources & Further Reading
Curriculum and reference review: 24 September 2026. These original notes teach clinical reasoning and recognition, not standalone prescribing or procedure protocols. International guidance supports the principles below; local pathways, resources and authorized supervision govern patient care. Faculty review is pending.
- PM&DC MBBS Curriculum 2024 — Medicine & Allied overview (printed page 20) and General Medicine section (from page 74)
- Acute assessment: Resuscitation Council UK: ABCDE · NICE adult sepsis recognition · Anaphylaxis guidance
- Cardiology: NICE acute coronary syndromes · Heart failure · Atrial fibrillation
- Respiratory: GINA 2026 asthma summary guide
- Gastrointestinal and renal care: NICE upper gastrointestinal bleeding · Acute kidney injury
- Endocrinology: 2024 multi-society hyperglycemic crises consensus · NICE thyroid disease
- Neurology: NICE stroke and TIA · Bacterial meningitis
- Allied care: NICE neutropenic sepsis · Rheumatoid arthritis · Self-harm assessment
- Continuity and safety: NICE delirium · Multimorbidity · WHO Medication Without Harm · WHO patient safety solutions
